

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

APPLICATION NO.: 09/277,575 ATTY. DOCKET NO.: V0139.70028US00

FILING DATE: March 27, 1999 CONFIRMATION NO.: 3748

APPLICANT: Martha Karen Newell

GROUP ART UNIT: 1644 EXAMINER: Francois P. Vandervegt

U.S. PATENT DOCUMENTS


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
RV	A1	4,724,234		Cone, Jr.	02-19-1988
	A2	6,133,946		Cavallaro et al.	10-17-2000
	A3	2003/0150022	A1	Newell et al.	08-07-2003
	A4	2004/00054291	A1	Rogers et al.	01-08-2004
	A5	2005/0042224	A1	Newell	02-24-2005
	A6	2005/0074882	A1	Newell	04-07-2005
	A7	2005/0158333	A1	Newell	07-02-2005


FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
RV	B1	WO	00/78941	A2	Newell	12/28/2000	
	B2	WO	03/031643	A2	Newell et al.	04/17/2003	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
RV	C1	Agrawal, S. et al. "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Med. Today</i> , Vol. 6, pp: 72-81, 2000	
	C2	Bouillaud, F. et al. "A sequence related to a DNA recognition element is essential for the inhibition by nucleotides of proton transport through the mitochondrial uncoupling protein," <i>The EMBO Journal</i> , Vol. 13, No. 8, pp: 1990-1997, 1994	
	C3	Branch, A. "A good antisense molecule is hard to find," <i>Trends in Biochem. Sci.</i> , Vol. 23, pp: 45-50, 1998	
	C4	Chirila, T. et al. "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides," <i>Biomaterials</i> , Vol. 23, pp: 321-342, 2002	
	C5	Crooke, S. <i>Antisense Research and Application</i> , (Ed. by S. Crooke), pp: 1-50, Springer-Verlag, 1999	
	C6	Eliopoulos, AG et al. "CD40 Stimulation Augments Apoptosis In Carcinoma Cell Lines," <i>J. Cellular Biochem</i> , (supplemental 19B), Abstract B8-123, pg. 271, 1995	
	C7	Lobato, M. et al. "Intracellular antibodies and challenges facing their use as therapeutic agents," <i>Trends in Molecular Medicine</i> , Vol 9, No. 9, pp: 390-396, 2003	
	C8	Morimoto, H. et al. "Overcoming Tumor Necrosis Factor and Drug Resistance of Humor Tumor Cell Lines by Combination Treatment with Anti-Fas Antibody and Drugs or Toxins," <i>Cancer Research</i> , 53(11), pp: 2591-2596, 1993	
	C9	Pihl-Carey, K. "Disease Drug Fails in Phase III," <i>BioWorld Today</i> , Vol. 10, pp: 1-2, 1999	

EXAMINER:  DATE CONSIDERED: 2/1/06



FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/277,575		ATTY. DOCKET NO.: V0139.70028US00	
				FILING DATE: March 27, 1999		CONFIRMATION NO.: 3748	
				APPLICANT: Martha Karen Newell			
				GROUP ART UNIT: 1644		EXAMINER: Francois P. Vandervegt	
Sheet	2	of	2				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C10	Palu, G. et al. "In pursuit of new developments for gene therapy of human diseases," <i>Journal of Biotech</i> , Vol. 68, pp: 1-13, 1999		
	C11	Stayton, P. et al. "Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics," <i>Journal of Controlled Releases</i> , Vol. 65, pp: 203-220, 2000		

EXAMINER: 	DATE CONSIDERED: 2/1/06
---------------	----------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]